Most Recent
Drug manufacturer Janssen wants to expand its high stakes case against Juno Pharmaceuticals over its HIV drug Prezista, alleging Juno's plans to launch a generic version of the drug threaten another one of its patents.
The prefab concrete specialist behind Sydney's Opal Tower has filed a lawsuit against Chubb Insurance seeking to force the insurer to cover its costs of defending two proceedings over the ill-fated building.
Telstra has been ordered to provide technology company Siemens Industry Software with all documents relating to the identity of account holders who may have infringed Siemens’ copyright.
A judge has rejected new evidence sought to be advanced by Hytera Communications in its IP battle with Motorola that Motorola deliberately delayed notifying Hytera of possible theft of its source code because it wanted to improve its market position.
Shine Lawyers has been given the go ahead to use two reports produced in three settled PFAS class actions as evidence in its latest case over the Defence Department's firefighting foam, with a judge saying any implied undertaking not to re-use the material lost force when the information became public.
A contradictor investigating alleged professional misconduct on the part of the legal team and funder behind a class action against failed Banksia Securities will subpoena the bank records of deceased class action lawyer and funder Mark Elliott and associated companies. Meanwhile, the barrister for the lead applicant has returned her brief on the eve of trial, on the advice of the bar ethics committee.
Owners of units in Sydney's Opal Tower have filed a lawsuit against the NSW Government and builder Icon after allegedly discovering more than 500 additional defects in the troubled building.
A private investment fund has failed again in its bid for damages from collapsed global advisory firm Babcock & Brown over a botched $1.4B acquisition of a US-based laundry equipment provider.
Ariosa Diagnostics is fighting to revoke a patent for noninvasive prenatal test owned by Sequenom, arguing it merely describes how to extract "incorporeal" genetic information that is naturally found within the DNA of an unborn foetus.
A judge has scolded the law firms behind competing shareholder class actions against Boral for delaying progress of the proceedings, but may wait until the High Court's ruling on the AMP class action beauty parade before deciding which of three potential class actions should move forward.